AlphAIAlphAI — Financial news for AI agents
fool.comSEP 82 min read$PCVX

Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing

Vaxcyte's CFO Andrew Guggenhime disposed of 2,705 shares to meet tax obligations, retaining 164,000 shares worth $10.12M. Vaxcyte, a clinical-stage biotech, has a $9B market cap and 95% one-year share price growth. Its lead vaccine candidate, VAX-24, is in clinical trials.

Original reporting
fool.com
Published Sep 8, 2026, 10:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 11:22 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing — source image
Source · fool.com
Decision brief

The 30-second read

$PCVXNeutralLow
01

Why it matters

The disclosed sale is routine and unlikely to affect valuation; however, the retained share count shows continued insider stake.

02

Market read

A modest insider sale with no material price impact; primarily of interest to compliance‑focused traders.

03

What to watch

The filing reveals the CFO still holds ~164,000 shares, indicating continued confidence despite the small sale.

Relevance 4/10Novelty 4/10Timing: post‑SEC Form 4 filing today

Background

Form 4 filings disclose insider transactions; investors monitor them for potential signals about company outlook.

Company-level read

Ticker impact

$PCVXNeutralHigh confidence
Context

CFO Andrew Guggenhime sold 2,705 shares to satisfy tax withholding via a Form 4 filing; not an open‑market sale.

Expected impact

minimal to none

Evidence & confidence

The transaction value is under $200k and was a routine tax‑withholding surrender, so market participants typically view it as non‑material.

Market effects

Sector

Limited; biotech sector sees no broader impact from a routine insider sale.

Regional

None; the filing is U.S.‑focused and does not affect regional markets.

Global

None

Counterpoint

What could challenge this read

If insiders are offloading shares, it could hint at concerns about upcoming trial data, but the tax‑withholding nature weakens this argument.

Key entities

  • person
    Andrew Guggenhime

    President and CFO of Vaxcyte, filing the insider transaction.

  • company
    Vaxcyte, Inc.

    Clinical‑stage biotech developing protein‑based vaccines, ticker PCVX.

Read at source← All news

Related articles

SEP 6
$PCVXMed

The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble

Vaxcyte (PCVX) reported a near-doubled net loss of $284.3M in Q2, with key Phase 3 trial results for its pneumococcal vaccine candidate VAX-31 expected by late 2026. The company has $2.5B in cash and added vaccine industry veterans to its board. Success hinges on upcoming clinical data.

yahoo.com3 min
AUG 5
$PCVXMed

Vaxcyte, Inc. (PCVX): Results of Operations and Financial Condition

Vaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half

SEC EDGAR 8-K6 min
SEP 20
$ADBEMed

A Pause on Advanced AI Is Wishful Thinking, But Adobe Stock Is a Buy Anyway

Adobe (ADBE) shares fell post-Q3 earnings despite beating estimates, citing forex headwinds. RPOs grew 8% YoY, the slowest since 2023. AI business ARR rose 150% but remains a small fraction of total ARR. New CEO Anil Chakravarthy will replace Shantanu Narayen. Analysts are mixed, with a mean target price of $269.70. The stock trades at 11x next fiscal year's EPS.

yahoo.com3 min